CV6 Therapeutics
1 known investors
Find your way into CV6 Therapeutics
113 people in our graph share verified history with the CV6 Therapeutics team — schools, employers, funds. One of them is your warm intro.
Awny Farajallahunlockedknows Robert D. Ladner · together at University of Medicine & Dentistry of New Jersey (UMDNJ) (overlapped)
×3knows the team · via Rutgers University
×8knows the team · via Saint Joseph's University
CV6 Therapeutics develops investigational cancer therapies designed for combination use with established standards of care, with a lead program (CV6-168) intended to enhance the activity of 5-fluorouracil and other thymidylate synthase-targeted therapies. The company is advancing CV6-168 through Phase 1a clinical development.
Founders & leadership
RD
Robert D. LadnerinCEO & FounderRobert D. Ladner is CEO and founder of CV6 Therapeutics, where he applies over 13 years of experience in drug development and clinical trials. His background includes expertise in translational cancer science, biochemistry, and advancing therapies targeting chemotherapy resistance.
Investors · 1
In the news
Frequently asked questions
- What does CV6 Therapeutics do?
- CV6 Therapeutics develops investigational cancer therapies designed for combination use with established standards of care, with a lead program (CV6-168) intended to enhance the activity of 5-fluorouracil and other thymidylate synthase-targeted therapies. The company is advancing CV6-168 through Phase 1a clinical development.
- Who founded CV6 Therapeutics?
- CV6 Therapeutics was founded by Robert D. Ladner.
- Who are CV6 Therapeutics's investors?
- CV6 Therapeutics's investors include Clarendon Fund Managers Ltd..